{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:39:10Z","timestamp":1792075150870,"version":"4.4.0"},"reference-count":17,"publisher":"Cambridge University Press (CUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:00:00Z","timestamp":1722816000000},"content-version":"unspecified","delay-in-days":217,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ASHE"],"published-print":{"date-parts":[[2024]]},"abstract":"Abstract<\/jats:title>\n \n Objective:<\/jats:title>\n \n Patients receiving hematopoietic stem cell transplants (HSCT) are at increased risk for\n Clostridioides difficile<\/jats:italic>\n infection (CDI). The purpose of this study was to assess the effectiveness of oral vancomycin prophylaxis (OVP) for CDI in HSCT patients.\n <\/jats:p>\n <\/jats:sec>\n \n Design:<\/jats:title>\n Single-center, retrospective cohort.<\/jats:p>\n <\/jats:sec>\n \n Setting:<\/jats:title>\n Tertiary care academic medical center in New Jersey.<\/jats:p>\n <\/jats:sec>\n \n Patients:<\/jats:title>\n Patients \u226518 years old during admission for the HSCT were included. Patients who were admitted <72 hours or who had an active CDI prior to HSCT day 0 were excluded.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Medical records of patients admitted between January 2015 and August 2022 to undergo an allogeneic or autologous HSCT were reviewed. The primary end point was the incidence of in-hospital CDI. Secondary end points included the incidence of vancomycin-resistant enterococci (VRE) bloodstream infections, VRE isolated from any clinical culture, gram-negative bloodstream infections, hospital survival, and hospital length of stay. Exploratory end points, including 1-year survival, relapse, and incidence of graft-versus-host disease, were also collected.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n A total of 156 HSCT patients were included. There was 1 case of CDI (1 of 81, 1.23%) in the OVP group compared to 8 CDI cases (8 of 75, 10.67%) in the no OVP group (\n P<\/jats:italic>\n = .0147). There were no significant (\n P<\/jats:italic>\n > .05) between-group differences in incidence of gram-negative bloodstream infections, hospital survival, and length of stay. There were zero clinical cultures positive for VRE.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n In-hospital incidence of CDI in HSCT patients was significantly decreased with OVP. Randomized controlled trials are needed in this high-risk population to assess the efficacy and risks of OVP for CDI.<\/jats:p>\n <\/jats:sec>","DOI":"10.1017\/ash.2024.90","type":"journal-article","created":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T04:14:05Z","timestamp":1722831245000},"source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of oral vancomycin as prophylaxis against\n Clostridioides difficile<\/i>\n infection in hematopoietic stem cell transplant patients"],"prefix":"10.1017","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4689-0809","authenticated-orcid":false,"given":"Kelly M.","family":"Reitmeyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brijesh","family":"Rana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2399-8948","authenticated-orcid":false,"given":"David","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9681-621X","authenticated-orcid":false,"given":"Jiyeon J.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5039-6301","authenticated-orcid":false,"given":"Arsheena","family":"Yassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6529-2911","authenticated-orcid":false,"given":"John P.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7940-4320","authenticated-orcid":false,"given":"Ahmed","family":"Abdul Azim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinki J.","family":"Bhatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navaneeth","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2024,8,5]]},"reference":[{"key":"S2732494X24000901_ref2","unstructured":"2. Centers for Disease Control and Prevention. C. diff (Clostridioides difficile) 2021. https:\/\/www.cdc.gov\/cdiff\/index.html. Accessed August 28, 2022"},{"key":"S2732494X24000901_ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.06.021"},{"key":"S2732494X24000901_ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2019.02.010"},{"key":"S2732494X24000901_ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy822"},{"key":"S2732494X24000901_ref3","unstructured":"3. Mada, PK , Alam, MU. Clostridioides difficile Infection 2023. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK431054\/. Accessed January 23, 2023"},{"key":"S2732494X24000901_ref12","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-10-363"},{"key":"S2732494X24000901_ref10","first-page":"217","article-title":"Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management","volume":"8","author":"O\u2019Driscoll","year":"2015","journal-title":"Infect Drug Resist"},{"key":"S2732494X24000901_ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91741-5"},{"key":"S2732494X24000901_ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2017.02.006"},{"key":"S2732494X24000901_ref15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac444"},{"key":"S2732494X24000901_ref17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz966"},{"key":"S2732494X24000901_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2003.09.021"},{"key":"S2732494X24000901_ref14","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa912"},{"key":"S2732494X24000901_ref7","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13790"},{"key":"S2732494X24000901_ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.629438"},{"key":"S2732494X24000901_ref4","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.01.059"},{"key":"S2732494X24000901_ref16","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001278"}],"container-title":["Antimicrobial Stewardship & Healthcare Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S2732494X24000901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T04:14:11Z","timestamp":1722831251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S2732494X24000901\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"alternative-id":["S2732494X24000901"],"URL":"https:\/\/doi.org\/10.1017\/ash.2024.90","relation":{},"ISSN":["2732-494X"],"issn-type":[{"value":"2732-494X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"e107"}}